Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 04.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 12.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | et forth by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
| 12.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | y set forth by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Dire |
| 29.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 23.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 09.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 05.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 12.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 08.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | et forth by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
| 31.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☐ ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 08.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | et forth by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
Stammdaten
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | Atara Biotherapeutics, Inc. |
|---|---|
| Ticker | ATRA |
| CIK | 0001604464 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 38,1 Mio. USD |
| Beta | -0,33 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 120,772,000 | 32,688,000 | 2.57 | 20,235,000 | -38,502,000 |
| 2025-09-30 | 10-Q | 3,453,000 | -4,303,000 | -0.32 | 30,167,000 | -36,634,000 |
| 2025-06-30 | 10-Q | 17,575,000 | 2,387,000 | 0.19 | 36,902,000 | -35,041,000 |
| 2025-03-31 | 10-Q | 98,149,000 | 38,010,000 | 3.50 | 62,038,000 | -55,072,000 |
| 2024-12-31 | 10-K | 128,940,000 | -85,403,000 | -11.41 | 109,098,000 | -97,283,000 |
| 2024-09-30 | 10-Q | 40,190,000 | -21,909,000 | -2.93 | 142,706,000 | -90,539,000 |
| 2024-06-30 | 10-Q | 28,640,000 | -19,049,000 | -3.10 | 117,284,000 | -110,868,000 |
| 2024-03-31 | 10-Q | 27,357,000 | -31,752,000 | -5.65 | 165,272,000 | -98,308,000 |
| 2023-12-31 | 10-K | 8,573,000 | -276,126,000 | -65.19 | 165,504,000 | 99,231,000 |
| 2023-09-30 | 10-Q | -69,797,000 | -16.40 | 188,788,000 | -50,838,000 | |
| 2023-06-30 | 10-Q | -71,108,000 | -16.91 | 246,439,000 | 7,454,000 | |
| 2023-03-31 | 10-Q | -74,771,000 | -0.72 | 302,083,000 | 64,960,000 | |
| 2022-12-31 | 10-K | -228,302,000 | -2.24 | 376,420,000 | 126,640,000 | |
| 2022-09-30 | 10-Q | -84,091,000 | -0.82 | 368,316,000 | 187,113,000 | |
| 2022-06-30 | 10-Q | 18,466,000 | 0.18 | 436,121,000 | 257,479,000 | |
| 2022-03-31 | 10-Q | -88,105,000 | -0.87 | 397,280,000 | 224,316,000 | |
| 2021-12-31 | 10-K | -340,141,000 | -3.63 | 468,127,000 | 279,614,000 | |
| 2021-09-30 | 10-Q | -84,664,000 | -0.90 | 449,923,000 | 310,141,000 | |
| 2021-06-30 | 10-Q | -83,793,000 | -0.91 | 456,791,000 | 331,538,000 | |
| 2021-03-31 | 10-Q | -78,335,000 | 529,637,000 | 399,037,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Nguyen AnhCo | Director, Officer, President and CEO | Open Market Sale | -58 | 5.08 | -294.64 | -0,5% | |
| 2026-03-02 | Grant-Huerta Yanina | Officer, Chief Accounting Officer | Open Market Sale | -1,603 | 5.08 | -8,144.84 | -12,8% | |
| 2026-03-02 | Grant-Huerta Yanina | Officer, Chief Accounting Officer | Open Market Sale | -377 | 5.08 | -1,915.91 | -3,0% | |
| 2026-03-02 | Grant-Huerta Yanina | Officer, Chief Accounting Officer | Open Market Sale | -100 | 5.08 | -508.30 | -0,8% | |
| 2026-03-02 | Grant-Huerta Yanina | Officer, Chief Accounting Officer | Open Market Sale | -24 | 5.08 | -121.85 | -0,2% | |
| 2026-03-02 | Nguyen AnhCo | Director, Officer, President and CEO | Open Market Sale | -1,442 | 5.09 | -7,335.45 | -11,5% | |
| 2026-03-02 | Nguyen AnhCo | Director, Officer, President and CEO | Open Market Sale | -1,298 | 5.09 | -6,601.63 | -10,4% | |
| 2026-03-02 | Nguyen AnhCo | Director, Officer, President and CEO | Open Market Sale | -198 | 5.08 | -1,005.64 | -1,6% | |
| 2026-01-12 | Panacea Innovation Ltd | 10% Owner | Open Market Sale | -80,554 | 6.07 | -489,019.17 | -768,9% | |
| 2025-11-17 | Grant-Huerta Yanina | Officer, Chief Accounting Officer | Open Market Sale | -74 | 13.19 | -976.13 | -1,5% | |
| 2025-11-17 | Nguyen AnhCo | Director, Officer, President and CEO | Open Market Sale | -56 | 13.19 | -738.53 | -1,2% | |
| 2025-11-17 | Nguyen AnhCo | Director, Officer, President and CEO | Open Market Sale | -2,859 | 13.19 | -37,698.77 | -59,3% | |
| 2025-11-17 | Grant-Huerta Yanina | Officer, Chief Accounting Officer | Open Market Sale | -85 | 13.19 | -1,120.98 | -1,8% | |
| 2025-11-17 | Grant-Huerta Yanina | Officer, Chief Accounting Officer | Open Market Sale | -1,645 | 13.19 | -21,690.97 | -34,1% | |
| 2025-08-18 | Grant-Huerta Yanina | Officer, Chief Accounting Officer | Open Market Sale | -55 | 11.61 | -638.50 | -1,0% | |
| 2025-08-18 | Grant-Huerta Yanina | Officer, Chief Accounting Officer | Open Market Sale | -1,668 | 11.61 | -19,372.15 | -30,5% | |
| 2025-08-18 | Grant-Huerta Yanina | Officer, Chief Accounting Officer | Open Market Sale | -86 | 11.61 | -998.72 | -1,6% | |
| 2025-08-18 | Nguyen AnhCo | Director, Officer, President and CEO | Open Market Sale | -57 | 11.61 | -661.94 | -1,0% | |
| 2025-08-18 | Nguyen AnhCo | Director, Officer, President and CEO | Open Market Sale | -1,620 | 11.62 | -18,819.54 | -29,6% | |
| 2025-08-18 | Nguyen AnhCo | Director, Officer, President and CEO | Open Market Sale | -1,281 | 11.62 | -14,878.82 | -23,4% | |
| 2025-08-15 | Panacea Innovation Ltd | 10% Owner | Open Market Purchase | 55,000 | 12.19 | 670,422.50 | +1054,1% | |
| 2025-07-17 | Panacea Innovation Ltd | 10% Owner | Open Market Purchase | 19,335 | 9.64 | 186,372.00 | +293,0% | |
| 2025-05-16 | Nguyen AnhCo | Director, Officer, President and CEO | Open Market Sale | -3,276 | 6.76 | -22,155.59 | -34,8% | |
| 2025-05-16 | Grant-Huerta Yanina | Officer, Chief Accounting Officer | Open Market Sale | -2,218 | 6.76 | -15,000.33 | -23,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.